Theriva Biologics Inc

For the period ended Dec 31, 2023. Filed Mar 25, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 25, 2024

TOVX$0.17-0.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Page
	PART I.	3

Item 1.	Business	5

Item 1A.	Risk Factors	31

Item 1B.	Unresolved Staff Comments	59

Item 1C.	Cybersecurity	59

Item 2.	Properties	60

Item 3.	Legal Proceedings	60

Item 4.	Mine Safety Disclosures	60

	PART II.	60

Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	60

Item 6.	[Reserved]	61

Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	61

Item 7A.	Quantitative and Qualitative Disclosures About Market Risk	68

Item 8.	Financial Statements and Supplementary Data	69

Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	108

Item 9A.	Controls and Procedures	108

Item 9B.	Other Information	109

Item 9C.	Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	109

	PART III.	110

Item 10.	Directors, Executive Officers and Corporate Governance	110

Item 11.	Executive Compensation	113

Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	123

Item 13.	Certain Relationships and Related Transactions, and Director Independence	124

Item 14.	Principal Accountant Fees and Services	125

	PART IV.	126
Item 15.	Exhibits and Financial Statement Schedules	126

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.

About this filing

Table of Contents